Thomas C. Harding

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Boulder, CO
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Thomas Harding
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Thomas C. Harding

Form 4 holding Senior Vice President and Chief Scientific Officer

Clovis Oncology, Inc.

Security class
Common Stock
Shares / value
19,487
Estimated value
$19,154
Report date
02 Nov 2022
Price
$0.9829
Ownership
Direct
Form 4 holding Senior Vice President and Chief Scientific Officer

Clovis Oncology, Inc.

Security class
Common Stock
Shares / value
3,801
Estimated value
$3,736
Report date
02 Nov 2022
Price
$0.9829
Ownership
By wife
Form 4 holding Senior Vice President and Chief Scientific Officer

Clovis Oncology, Inc.

Security class
Restricted Stock Units
Shares / value
9,063
Estimated value
Report date
01 Nov 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Senior Vice President and Chief Scientific Officer

Clovis Oncology, Inc.

Security class
Restricted Stock Units
Shares / value
907
Estimated value
Report date
01 Nov 2022
Price
Ownership
By wife
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Thomas C. Harding

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .